US › Healthcare

Summit Therapeutics PLC (SMMT)

US · Healthcare · Biotechnology

$13.76+5.48%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-215.7M
Profit YoY
+6.9%
EPS
$-0.28
EPS estimate
$-0.26

EPS came in at -0.28 against a street estimate of -0.26 — a miss of 7.7%.

Key statistics

Market cap
$10.39B
Forward P/E
3.7
P/B
16.49
Book value
$0.70
EPS (TTM)
$-1.11
52-week high
$30.98
52-week low
$12.25
50-day MA
$14.77
200-day MA
$17.05
Beta
-1.26

Analyst view

Analysts rate Summit Therapeutics PLC a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $28.21.

Shareholding

Insiders
80.89%
Institutions
15.41%

Largest institutional holders

FundStake
Baker Bros Advisors LP4.59%
Vanguard Group Inc1.41%
FMR Inc1.37%
BlackRock Inc1.22%
T. Rowe Price Associates, Inc.1.04%
State Street Corp0.89%
Vanguard Capital Management, LLC0.72%
Vanguard Portfolio Management, LLC0.66%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Summit Therapeutics PLC — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.